Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/36347
Title: Integrated manufacturing of mRNA nanomedicines using thermoreversible aqueous biphasic systems and ionic liquids
Author: Sousa, Maria I.
Freire, Mara G.
Silva, Francisca A. e
Pedro, Augusto Q.
Keywords: mRNA nanomedicines
Ionic liquid
Integrated manufacturing processes
Thermoreversible aqueous biphasic system
In vitro transcription
T7 RNA polymerase
Issue Date: Sep-2022
Abstract: The COVID-19 pandemic has unlocked the potential of messenger RNA (mRNA) vaccines as an effective tool to contain infectious diseases outbreaks. Over conventional vaccines, mRNA vaccines show advantages, namely improved safety and efficacy, and the possibility of repeatedly administration. In addition to infectious diseases, mRNA offer enhanced therapeutic approaches for a wide range of diseases including cancer, myocardial ischemia, genetic diseases, among others [1]. However, mRNA nanomedicines production is still complex and expensive, requiring improved technologies to produce more stable and widely accessible products by meeting a timely and sufficient manufacturing capacity. If properly engineered, ionic liquids (ILs) can improve the stability of RNA [2] and contribute to the achievement of highly selective purification processes when applied as components of aqueous biphasic systems (ABS) [3]. To overcome the described bottlenecks, this work proposes the integration of production and clarification steps of mRNA manufacturing processes using thermoreversible ABS comprising ILs to simplify subsequent purification steps. So far, we have accomplished the production of mRNA by in vitro transcription, and its purification using conventional methods, followed by the study of mRNA stability and integrity in ILs with different chemical structures. Based on these results, ongoing work is focused on the selection of the best production-clarification platform resorting to thermoreversible IL-based ABS. In conclusion, the integrated production-clarification platform herein developed can be essential to overcome the challenges of mRNA nanomedicines production, namely by lowering costs and environmental impact of current manufacturing processes while improving mRNA stability, yield, and speed of production.
Peer review: yes
URI: http://hdl.handle.net/10773/36347
Appears in Collections:CICECO - Comunicações

Files in This Item:
File Description SizeFormat 
Sousa et al_BPP_2022.pdf175.21 kBAdobe PDFView/Open


FacebookTwitterLinkedIn
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.